FiercePharmaAsia—Takeda’s assets spinoff, AstraZeneca’s China JV, Biocon’s biologics plant

1st December 2017 Uncategorised 0

Takeda transferred some early cancer candidates to a startup it’s incubating, AstraZeneca put its R&D capabilities in China in the hands of a newly formed joint venture, Biocon has resolved FDA concerns of a plant crucial to potential approval of its Herceptin biosimilar, and more.

More: FiercePharmaAsia—Takeda’s assets spinoff, AstraZeneca’s China JV, Biocon’s biologics plant
Source: fierce